Several biopharmaceutical companies took it on the chin Wednesday, led by Aegerion Pharmaceuticals, which plunged on weak earnings and an analyst downgrade. Aegerion /quotes/zigman/624094/delayed /quotes/nls/aegr AEGR was off …
and VANCOUVER, B.C., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) …
The company intends to list its common stock on the Nasdaq under the symbol “AEGR.” (Reporting by Sayantani Ghosh in Bangalore;) Our Standards:The Thomson Reuters Trust Principles.
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) 16.5% HIGHER; reported Q2 EPS of ($0.66), $ ... announced the …
Aegerion Pharmaceuticals, Inc. AEGR announced that it has entered into a definitive ... Post completion, each outstanding share of Aegerion’s common stock will be exchanged for 1.0256 shares of QLT’s common stock. QLT will change its …
April 19, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company ... and risks associated with volatility in the Company's stock price as a newly public company. Existing and …
Aegerion Pharmaceuticals, Inc. AEGR announced its plans to reduce its global workforce ... Aegerion is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF, Anika Therapeutics Inc. …
SAN FRANCISCO (Reuters) - Several of the top 10 investors in Aegerion Pharmaceuticals Inc AEGR.O are pushing the company to oust Chief Executive Marc Beer and consider selling itself after a year-long slump in its stock price, …